"The US Food and Drug Administration (FDA) has approved an extended-release capsule formulation of carbidopa-levodopa (Rytary, IPX066, Impax Pharmaceuticals) for the treatment of Parkinson's disease (PD), postencephalitic parkinsonism, an"...
ELDEPRYL (selegiline hcl) is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy.
Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of 'off' time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).
DOSAGE AND ADMINISTRATION
ELDEPRYL (selegiline hcl) is intended for administration to Parkinsonian patients receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment. The recommended regimen for the administration of ELDEPRYL (selegiline hcl) is 10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. There is no evidence that additional benefit will be obtained from the administration of higher doses. Moreover, higher doses should ordinarily be avoided because of the increased risk of side effects.
After two to three days of selegiline treatment, an attempt may be made to reduce the dose of levodopa/carbidopa. A reduction of 10 to 30% was achieved with the typical participant in the domestic placebo controlled trials who was assigned to selegiline treatment. Further reductions of levodopa/carbidopa may be possible during continued selegiline therapy.
ELDEPRYL (selegiline hcl) capsules are available containing 5 mg of selegiline hydrochloride. Each aqua blue capsule is band imprinted with the Somerset logo on the cap and "Eldepryl (selegiline hcl) 5 mg" on the body.
They are available as:
NDC 39506-022-60 bottles of 60 capsules.
NDC 39506-022-30 bottles of 300 capsules.
Store at controlled room temperature, 59° to 86°F (15° to 30°C).
Somerset Pharmaceuticals, Inc. Tampa, FL 33607. Literature issued July 1998. FDA Rev date: 2/15/2001This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/15/2008
Additional Eldepryl Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.